Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1342 - Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor

Date

09 Sep 2017

Session

Poster display session

Presenters

Keunchil Park

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

K. Park1, F. Ciardiello2, T. Hida3, W. Lim4, C. Lin5, H. Murakami6, M. Nishio7, F. Cantero8, V. Cattan8, C. Gabarroca9, E. Gandossi8, L. Paz-Ares10

Author affiliations

  • 1 Division Of Heamatology/oncology, Department Of Medicine, Samsung Medical Center, 06351 - Seoul/KR
  • 2 U.o.c. Di Oncologia Medica E Di Ematologia, Università degli Studi della Campania "Luigi Vanvitelli", 80131 - naples/IT
  • 3 Department Of Thoracic Oncology, Aichi Cancer Center, 464-8681 - Nagoya/JP
  • 4 Clinical Trial And Epidemiological Sciences, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 5 Department Of Oncology, National Taiwan University Hospital, 10002 - Taipei/TW
  • 6 Division Of Thoracic Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 7 Department Of Thoracic Medical Oncology, The Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 8 Department Of Oncology R&d, Servier, 92284 - Suresnes/FR
  • 9 Department Of Oncology Biostatistics, Servier, 92284 - Suresnes/FR
  • 10 Medical Oncology, Hospital Universitario 12 de Octubre, Madrid/ES
More

Resources

Abstract 1342

Background

EGFR-mutated NSCLC patients treated with EGFR TKI ultimately develop resistance to therapy. Mechanisms of resistance include aberrant signalling of MET, AXL and FGFR. Inhibition of these receptors should thus abrogate their downstream signalling and restore sensitivity to EGFR TKI. S 49076 is a potent ATP-competitive TKI, which targets MET, AXL and FGFR1/2/3 at clinically relevant doses. It showed strong activity in preclinical assays against EGFR mutated MET amplified cell lines to overcome the resistance to EGFR TKI. This study evaluates the relevance of targeting MET and/or AXL dysregulation to overcome acquired non EGFR-T790M-mediated resistance to EGFR-TKI.

Trial design

The phase I/II is an international, open-label study to evaluate the safety and activity of S 49076 in combination with gefitinib in stage IIIb-IV NSCLC patients who progress on EGFR TKI (1st and 2nd generation), harbouring MET and/or AXL dysregulation without EGFR-T790M mutation. The phase I is a single arm dose-finding part of S 49076 in combination with standard dose of gefitinib. The primary objective is to determine the recommended phase 2 dose (RP2D) based on the dose-limiting toxicities and safety assessments. The secondary objectives are to evaluate the pharmacokinetic profile of both drugs and the anti-tumour activity of the combination. S 49076 and gefitinib are administered orally once daily over a continuous 28-day cycle with doses ranging from 500mg to 600mg. Dose levels are allocated using a modified Bayesian Continual Reassessment Method. This study part is active and recruiting over 5 countries across Asia and Europe. The end of phase I is expected in Q3 2017. A non-randomised and non-comparative phase II part will then evaluate the anti-tumour activity of S 49076 at the RP2D in combination with gefitinib in cohorts of patients with MET and/or AXL dysregulation. The primary objective will be to determine the objective response rate according to RECIST and the secondary objectives will be to evaluate survival rate, progression free survival, clinical benefit rate and response duration as well as safety. An interim analysis will be performed in each cohort for futility.

Clinical trial identification

EudraCT 2015-002646-31

Legal entity responsible for the study

Institut de Recheches Internationales Servier

Funding

Institut de Recherches Internationales Servier

Disclosure

K. Park: Servier study international coordinator and investigator. F. Ciardiello, W. Lim, C-C. Lin: Servier study national coordinator and investigator. T. Hida, H. Murakami, M. Nishio: Servier study investigator. F. Cantero, V. Cattan, C. Gabarroca, E. Gandossi: Servier employee. L. Paz-Ares: Study Servier national coordinator and investigator.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.